ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries, announced that is has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.
As a partner for clinical development, ICON will provide Shire with a full range of services including site and country feasibility, ethics, and regulatory submissions, clinical trial monitoring, project management, site, and study team support, medical management, and medical data review. Shire will also utilise ICON Central Laboratories’ extensive test menu from its global network of laboratories.
“We are proud that Shire Specialty Pharmaceuticals has selected ICON as a global partner and it is another endorsement of ICON’s expertise in operating under strategic partnership models,” commented Ciaran Murray, CEO, ICON plc. “ICON’s success is based on the right blend of development services and global testing facilities.. We look forward to building on our successful relationship with Shire to help them realize efficiencies as they seek to bring new products to market.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.